Borean aims to leverage the trimeric properties of one human protein, tetranectin, to develop second-generation protein therapeutics to treat autoimmune disease and cancer. Its first candidate is a TNF-alpha antagonist in preclinical testing for autoimmune diseases, but the company also has ongoing early work on several undisclosed oncology targets.
Gustav Wieds Vej 10
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
With positive data versus radiation therapy in KEYNOTE-689, Merck & Co. files for approval in perioperative head and neck cancer, adding to additional claim in that cancer type.
Chief medical officer Eliav Barr, responsible for overseeing clinical development, talked to Scrip in an interview at Merck’s headquarters about the company’s pipeline diversification.
Already a frontrunner in developing the KRAS G12D inhibitor class, analysts think Revolution Medicines could seal its leadership by combining zoldonrasib with other agents in its portfolio.